Epicrispr Raises $90M Series C to Advance EPI-321 Trial

Epicrispr Biotechnologies closed a $90M oversubscribed Series C on August 11, 2026. Octagon Capital and Janus Henderson Investors co-led the round, with a broad group of institutional, strategic, and specialist healthcare investors participating.

The money is aimed at moving EPI-321, Epicrispr's first-in-human epigenetic therapy for facioscapulohumeral muscular dystrophy, toward pivotal studies. It will also support the company's broader pipeline, Gene Expression Modulation System, and manufacturing capabilities.

The larger signal is not simply that another biotech raised a large round. Epicrispr reached the Series C market with a clinical program, completed dose escalation, and early company-reported human data, which gives investors something more concrete to underwrite than platform potential alone.

What Happened

The $90M financing was co-led by Octagon Capital and Janus Henderson Investors. Fidelity Management & Research Company, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, funds managed by abrdn Inc., Angelini Ventures, Readout Capital, and existing investors also participated, while Anran Li, Ph.D., of Octagon Capital is joining Epicrispr's board.

Epicrispr previously announced a $55M Series A in July 2022 and a $68M first close of Series B in March 2025. Adding those disclosed amounts to the Series C puts the company's announced financing at least $213M, although Epicrispr did not state a total-funding figure or disclose its valuation in the latest release.

That capital progression mirrors the company's operating progression. The Series A supported a preclinical platform and pipeline, the Series B helped move EPI-321 into human studies, and the Series C is intended to fund the harder work of preparing a lead program for pivotal development while keeping the rest of the pipeline alive.

Why EPI-321 Matters

EPI-321 is an investigational, one-time therapy designed for facioscapulohumeral muscular dystrophy, or FSHD. The disease is driven by abnormal expression of DUX4, a gene that damages skeletal muscle, and there are currently no approved disease-modifying therapies for the condition.

Epicrispr's approach uses an AAVrh74 vector to deliver a compact, non-cutting epigenetic editor to muscle. Instead of permanently changing the underlying DNA sequence, the therapy is designed to remethylate the D4Z4 region near DUX4 and suppress the toxic gene expression associated with FSHD.

That difference is central to the company's thesis. Gene editing is often discussed as rewriting DNA, while epigenetic editing is closer to controlling which genetic instructions are turned on, turned down, or silenced, potentially opening a different route to durable treatment.

What the Early Clinical Data Show

EPI-321 is being studied in an open-label Phase 1/2 trial. Epicrispr reported that, as of a May 12, 2026 data cutoff, 9 patients had been treated across two dose cohorts and no serious adverse events had been reported at that time.

The company also said the first 3 evaluable patients showed increased lean muscle volume at 6 months, averaging about 370 mL, or 0.8 pounds. Epicrispr later announced that all 12 participants had been enrolled and dosed, with additional clinical data expected at the World Muscle Society Annual Congress in September 2026.

Those observations are encouraging, but they are not proof of efficacy. The study is small and open-label, the interim results were reported by the company, and pivotal testing will have to show whether the biological and imaging signals translate into durable, meaningful patient benefit.

The Platform Behind the Program

Epicrispr's Gene Expression Modulation System, or GEMS, combines a DNA-binding protein, a customized guide RNA, and modulator proteins. The company is building libraries of compact effectors and DNA-binding proteins, plus computational and experimental methods intended to improve guide design, on-target activity, and delivery.

Scientific founder Lei Stanley Qi, Ph.D., helped establish key CRISPR activation and interference tools and developed CasMINI at Stanford. CEO Amber Salzman, Ph.D., now leads the company through the less glamorous but decisive work of clinical execution, regulatory preparation, manufacturing, and financing.

The broader pipeline includes EPI-331 for Duchenne muscular dystrophy and EPI-141 for retinitis pigmentosa 4, both listed in research. That creates platform upside, but the near-term value of the company will still be shaped disproportionately by EPI-321 and the quality of the data it generates.

Why Investors Are Leaning In Now

Biotech investors have become less patient with platforms that promise many programs but arrive with limited clinical evidence. Epicrispr's Series C comes after the company moved its lead asset into human testing, reported early biological and imaging signals, and completed enrollment and dose escalation.

The syndicate reflects that shift from scientific possibility toward execution risk. Specialist healthcare investors, a global asset manager, strategic venture arms, and large institutions are backing a company that must now prove it can move from an early signal to a pivotal-ready program.

There is still plenty that can go wrong. AAV delivery, safety, durability, manufacturing, endpoint selection, and the translation of muscle-volume changes into functional benefit all remain demanding questions, which is exactly why the financing matters more as operating runway than as a victory lap.

What the Series C Signals

Epicrispr is not merely financing another preclinical expansion. The company is raising capital to test whether programmable epigenetic medicine can become a clinical modality, beginning with a disease where the biological target is clear and the unmet need remains severe.

If EPI-321 continues to produce credible safety, biomarker, imaging, and functional evidence, Epicrispr could give the field a concrete example of regulating disease-causing gene expression without cutting DNA. If the signal weakens under larger and more rigorous testing, the market will learn just as much about the limits of the approach.

For operators, the business lesson is plain: platform stories become financeable on better terms when a team converts technical differentiation into clinical milestones that investors can evaluate. Epicrispr now has the capital to attempt that conversion at pivotal scale, and the next data will carry more weight than the size of the round.